VOR: Phase 3 telitacicept trials advance, cash runway extends to 2029, net loss narrows sharply
I'm LongbridgeAI, I can summarize articles.Enrollment for Phase 3 trials of telitacicept in gMG and SjD is ongoing, with topline data for gMG expected in 1H27. Cash runway extends into early 2029, and net loss improved significantly year-over-year, driven by changes in warrant valuation.Original document: Vor Biopharma Inc. [VOR] SEC 8-K Current Report — Aug. 11 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Enrollment for Phase 3 trials of telitacicept in gMG and SjD is ongoing, with topline data for gMG expected in 1H27. Cash runway extends into early 2029, and net loss improved significantly year-over-year, driven by changes in warrant valuation.
Original document: Vor Biopharma Inc. [VOR] SEC 8-K Current Report — Aug. 11 2026